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Low-Level Transcutaneous Electrical Vagus Nerve 
Stimulation (LLTS) Suppresses Atrial Fibrillation 
Patients with paroxysmal atrial fibrillation (AF) were 
randomized to 1 hour of 20 Hz LLTS (n= 20) or sham 
control (n= 20) by attaching a flat metal clip onto the tragus 
in the right ear. AF was induced by burst atrial pacing at 
baseline and after 1 hour of LLTS or sham treatment. 
Blood samples from the coronary sinus and the femoral 
vein were collected at those time points and analyzed for 
inflammatory cytokines, including tumor necrosis factor 
alpha and C-reactive protein. Pacing-induced AF duration 
decreased significantly by 6.3 ± 1.9 min compared with 
baseline in the LLTS but not in the control group 
(p=0.002). AF cycle length increased significantly from 
baseline by 28.8 ± 6.5 ms in the LLTS but not in the control 
group (p= 0.0002). Femoral vein but not coronary sinus 
tumor necrosis factor (TNF)-alpha and C-reactive protein 
levels decreased significantly only in the LLTS group. The 
authors concluded that LLTS suppresses AF and decreases 
inflammatory cytokines in patients with paroxysmal AF, 
supporting a role of neuromodulation to treat AF 
(Stavrakis S et al, J Am Coll Cardiol 2015;65:867-875).   
Among Patients with Early Repolarization Syndrome, 
Programmed Stimulation Does not Predict Future 
Arrhythmic Events 
In a multicenter study, 81 patients, aged 36+13 years, 
with early repolarization (ER) syndrome and aborted 
sudden death due to ventricular fibrillation (VF) 
underwent an electrophysiology study (EPS). VF was 
inducible in only 18 of 81 (22%) patients. During follow-
up of 7.0 ± 4.9 years, 6 of 18 (33%) patients with inducible 
VF, and 21 of 63 (33%) noninducible patients experienced 
VF recurrences (p= NS). VF storm occurred in 3 inducible 
and 4 noninducible patients. VF inducibility was not 
associated with maximum J-wave amplitude or J-wave 
distribution (inferior, odds ratio -OR: 0.96; lateral, OR: 
1.57; inferior and lateral, OR: 0.83; all p = NS), which have 
previously been shown to predict outcome in patients with 
an ER pattern. The authors concluded that EPS did not 
enhance risk stratification in ER syndrome (Mahida S et al, 
J Am Coll Cardiol 2015;65:151-159).   
ICD Therapy is an Effective Strategy in Patients With 
Brugada Syndrome, Treating Potentially Lethal 
Arrhythmias in 17% of Patients but also in 13% of 
Asymptomatic Patients, Albeit at Increased Risk for 
Complications in 16% / Risk Stratification by Means of 
EPS Might Identify Asymptomatic Patients at Risk  
Among 176 consecutive Brugada syndrome patients, 
spontaneous sustained ventricular arrhythmias (VAs) 
occurred in 30 patients (17%) at follow-up of 7 + 4.8 years. 
Eight patients (4.5%) died. Appropriate ICD shocks 
occurred in 28 (15.9%), inappropriate shocks in 33 patients 
(18.7%), and electrical storm in 4 (2.3%). Device-related 
complications occurred in 28 patients (15.9%). In 
multivariate analysis, aborted sudden cardiac death and 
VA inducibility on electrophysiology studies (EPS) were 
independent predictors of appropriate shock occurrence. 
The authors concluded that ICD therapy was an effective 
strategy in Brugada syndrome, treating potentially lethal 
arrhythmias in 17% of patients during long-term follow-
up, but also in 13% of asymptomatic patients. Risk 
stratification by EPS may identify asymptomatic patients 
at risk for arrhythmic events. ICDs are frequently 
associated with device-related complications (Conte G et 
al, J Am Coll Cardiol 2015;65:879–888).   
Swedish Registries: Benefit of Anticoagulation 
Unlikely in Patients With Atrial Fibrillation (AF) and 
a CHA2DS2-VASc Score of 1 
According to a retrospective study of 140,420 patients 
with AF, among those with a CHA2DS2-VASc score of 1, 
the annual event rates varied between 0.5% and 0.9%; 
women were truly low risk, with an annual ischemic stroke 
rate of only 0.1% to 0.2%. For men, the ischemic stroke 
rate was between 0.5% and 0.7%. When the endpoint 
included diagnoses of TIA, pulmonary embolism, arterial 
embolism, and stroke not specified as ischemic or 
hemorrhagic, the annual event rate for men was 1.3%. The 
authors concluded that the risk of ischemic stroke in 
patients with AF and a CHA2DS2-VASc score of 1 seems 
to be lower than previously reported (Friberg L et al, J Am 
Coll Cardiol 2015;65:225–32).   
Taiwanese Study: Anticoagulation Should be 
Considered for AF Patients With 1 Additional Stroke 
Risk Factor Given their High Risk of Ischemic Stroke  
A retrospective study investigated the risk of ischemic 
stroke in patients with a single additional stroke risk factor, 
i.e., CHA2DS2-VASc score = 1 (males) or 2 (females). 
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Among 12,935 male AF patients with a CHA2DS2-VASc 
score of 1, 1,858 patients (14.4%) had an ischemic stroke 
during follow-up (5.2 + 4.3 years), with an annual stroke 
rate of 2.75%. Ischemic stroke risk ranged from 
1.96%/year for men with vascular disease to 3.5%/year for 
those 65 to 74 years of age. For 7,900 females with AF and 
a CHA2DS2-VASc score of 2, 14.9% experienced ischemic 
stroke for an annual stroke rate of 2.55%. Ischemic stroke 
risk increased from 1.91%/year for women with 
hypertension to 3.34%/year for those 65 to 74 years of age. 
The authors concluded that among risk factors, age 65 to 
74 years is associated with the highest stroke rate. Oral 
anticoagulation should be considered for AF patients with 
1 additional stroke risk factor given their high risk of 
ischemic stroke (Chao T et al, J Am Coll Cardiol 
2015;65:635–642).   
ITALIC Trial: Bleeding and Thrombotic Event Rates 
Not Different Between 6- & 24-Month DAPT After PCI 
with 2nd-Generation DES/6-Month DAPT Non-inferior 
to 24-Month DAPT in Good Aspirin Responders  
Of 2,031 enrolled patients undergoing implantation of 
everolimus-eluting stents with confirmed nonresistance to 
aspirin, 941 patients were randomized to 24-month and 
953 to 6-month dual antiplatelet therapy (DAPT). The 
primary endpoint (death, myocardial infarction, urgent 
target vessel revascularization, stroke, and major bleeding 
at 12 months post-stenting) was no different (24-month: 
1.5% vs 6-month: 1.6%; p = NS). 6-month was noninferior 
to 24-month DAPT. There were no significant differences 
in stent thrombosis or bleeding complications. In the 792 
(44%) high-risk patients with ACS, primary and secondary 
endpoints did not significantly differ (hazard ratio: 1.7; p 
= NS). The authors concluded that rates of bleeding and 
thrombotic events were not significantly different 
according to 6- vs 24-month DAPT after PCI with new-
generation DES in good aspirin responders (Gilard M et al, 
J Am Coll Cardiol 2015;65:777–786).   
Meta-Analysis: Short-Term (≤6 Months) Dual 
Antiplatelet Therapy (DAPT) After Implantation of 
Drug-Eluting Stents Produced Similar Rates of Major 
Adverse Cardiac Events (MACE) But Significantly 
Less Bleeding Than Longer-Term (≥1 Year) DAPT  
Metaanalysis of 4 randomized trials including 8,180 
patients indicated that at 1-year, short-term (≤6 months) 
DAPT was associated with similar rates of MACE (hazard 
ratio - HR: 1.11; p= NS), but significantly lower rates of 
bleeding (HR: 0.66; p= 0.03) versus prolonged DAPT (1 
year). Comparable results were apparent between DAPT 
discontinuation and 1-year follow-up (for MACE: HR: 
1.20; p = NS) (for bleeding: HR: 0.44; p= 0.03). There 
were no significant differences in 1-year rates of MACE 
among 3-month vs 1-year DAPT, 6-month vs 1-year 
DAPT, or 3-month vs 6-month DAPT. The authors 
concluded that compared with prolonged DAPT, short-
term DAPT is associated with similar rates of MACE but 
lower rates of bleeding after DES placement (Palmerini T 
et al, J Am Coll Cardiol 2015;65:1092-1102).   
Occupational Health Hazards of Working in the 
Interventional LaboratoryMore Work-Related 
Musculoskeletal Pain but No Cancer 
Among 1,543 Mayo Clinic employees (aged 43 ± 11.3 
years, 33% male) working in interventional cardiology or 
radiology laboratories responding (57%) to a survey, 1,042 
(67.5%) were involved with procedures utilizing radiation. 
They reported experiencing work-related pain more often 
than the control group before (54.7% vs 44.7%; p< 0.001) 
and after adjustment for confounding factors (odds ratio: 
1.67; p< 0.001). Musculoskeletal pain varied significantly 
by job description, with the highest incidence reported by 
technicians (62%) and nurses (60%) followed by 
physicians (44%) and trainees (19%; p< 0.001). There was 
no difference in cancer prevalence between groups (9% vs 
9%) (Orme NM et al, J Am Coll Cardiol 2015;65:820-
826).   
Circulating Levels of Amyloid Beta are Predictive of 
Cardiovascular Mortality in Patients With Established 
Coronary Heart Disease (CHD)  
Amyloid beta peptide, a major protein constituent of 
neuritic plaques in Alzheimer disease, with a central role 
in vascular inflammation pathophysiology, was measured 
(amyloid beta 40 form: Abeta40) in blood samples 
collected from 1,464 patients with CHD. Abeta40 
independently predicted cardiovascular (CV) death and 
major adverse cardiac events (MACE) in patients with 
CHD (p< 0.05 for all). Cohort-based analysis revealed that 
Abeta40 levels were significantly and independently 
associated with arterial stiffness progression, incident 
subclinical atherosclerosis and CHD. The authors 
concluded that measuring blood levels of Abeta40 
identified patients at high risk for CV death. 
(Stamatelopoulos K et al, J Am Coll Cardiol 2015;65:904-
916).  
Cvlprit: In Patients Undergoing Primary-PCI for 
STEMI, Complete Revascularization During Index 
Admission Confers Significantly Fewer MACE at 
12 Months Than When Only the IRA is Treated 
In CvLPRIT (Complete versus Lesion-only Primary 
PCI trial), 296 patients with STEMI undergoing primary 
PCI (P-PCI) in 7 UK centers were randomized to either in-
hospital complete revascularization (either at the time of 
P-PCI or before hospital discharge) (n= 150) or infarct-
related artery (IRA)-only revascularization (n= 146). The 
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primary endpoint (all-cause death, recurrent myocardial 
infarction -MI, heart failure, and ischemia-driven 
revascularization within 12 months), but not death or MI, 
was reduced with complete compared with IRA-only 
revascularization (10% vs 21.2%; hazard ratio: 0.45; p= 
0.009). A trend toward benefit was seen early after 
complete revascularization (p=0.055 at 30 days). The 
authors concluded that in patients presenting for P-PCI 
with multivessel disease, index admission complete 
revascularization significantly lowered the rate of the 
composite primary endpoint at 12 months compared with 
treating only the IRA (Gershlick AH et al, J Am Coll 
Cardiol 2015;65:963-972). N.B. The 2 randomized trials, 
PRAMI & CvLPRIT, reporting reduced MACE for PCI on 
non–infarct-related stenotic coronary arteries, have led to 
withdrawal of class III practice guideline 
recommendations not to treat significant non–infarct-
related stenoses in patients with STEMI and multivessel 
disease undergoing primary angioplasty.  
PARADIGM-HF: Angiotensin Receptor Neprilysin 
Inhibition Compared With Enalapril Reduces the Risk 
of Clinical Progression in Surviving Patients With 
Heart Failure 
Therapy with angiotensin-neprilysin inhibitor LCZ696 
(400 mg daily) compared with enalapril (20 mg daily) in 
8399 patients with heart failure and reduced ejection 
fraction led to fewer patients needing intensification of 
anticongestive treatment (520 vs 604; hazard ratio-HR, 
0.84; P=0.003) or visiting the emergency room for 
worsening heart failure (HR, 0.66; P=0.001). The LCZ696 
group had 23% fewer hospitalizations for worsening heart 
failure (P<0.001) (evident within the first 30 days) and 
were less likely to require intensive care (18% rate 
reduction, P=0.005), to receive inotropic agents (31% risk 
reduction, P<0.001), and to have implantation of a heart 
failure device or cardiac transplantation (22% risk 
reduction, P=0.07). LCZ696 led to an early and sustained 
reduction in biomarkers of myocardial wall stress and 
injury (N-terminal pro–B-type natriuretic peptide and 
troponin) vs enalapril. The authors concluded that 
angiotensin-neprilysin inhibition prevents clinical 
progression of surviving patients with heart failure more 
effectively than angiotensin-converting enzyme inhibition 
(Packer M et al, Circulation 2015; 131: 54-61).   
ORBIT-AF: Bridging Anticoagulation is Associated 
With Higher Risk of Bleeding and Adverse Events 
The Outcomes Registry for Better Informed Treatment 
of Atrial Fibrillation (ORBIT-AF) recorded temporary 
interruptions of oral anticoagulation for a procedure. Of 
7372 patients treated with oral anticoagulation, 2803 
overall interruption events occurred in 2200 patients (30%) 
at a median of 2 years. Bridging was used in 24% (n=665), 
mostly with low-molecular weight heparin (73%, n=487) 
and unfractionated heparin (15%, n=97). Bridged patients 
were more likely to have had prior cerebrovascular events 
(22% vs 15%; P=0.0003) and mechanical valves (9.6% vs 
2.4%; P<0.0001); however, there was no difference in 
CHA2DS2-VASc scores (scores ≥2 in 94% vs 95%; 
P=0.5). Bleeding events were more common in bridged 
than non-bridged patients (5% vs 1.3%; odds ratio-OR, 
3.84; P<0.0001). The incidence of myocardial infarction, 
stroke or systemic embolism, major bleeding, 
hospitalization, or death within 30 days was also 
significantly higher in patients receiving bridging (13% vs 
6.3%; OR, 1.94; P=0.0001) (Steinberg PA et al, 
Circulation 2015;131:488-494).  
Meta-Analysis for Myocardial Infarction (MI) With 
Nonobstructive Coronary Arteries (MINOCA): 6% 
Prevalence / More Likely in Younger and Female 
Patients and with Lower All-Cause Mortality at 12 
Months (4.7% vs 6.7%) Compared With MI With 
Obstructive Coronary Artery Disease  
According with a meta-analysis of 28 publications, the 
prevalence of MINOCA was 6% with a median patient age 
of 55 years and 40% women. However, in comparison with 
those with MI associated with obstructive coronary artery 
disease, patients with MINOCA were more likely to be 
younger and female but less likely to have hyperlipidemia. 
All-cause mortality at 12 months was lower in MINOCA 
compared with MI associated with obstructive coronary 
artery disease (4.7% vs 6.7%). Typical MI on cardiac 
magnetic resonance imaging is found in only 24% of 
patients, myocarditis in 33% and no significant 
abnormality in 26%. Coronary artery spasm was inducible 
in 27% of MINOCA patients, and thrombophilia disorders 
were detected in 14% (Pasupathy S et al, Circulation 2015; 
131: 861-870)  
Dabigatran and Rivaroxaban Confer Great Risk in 
Dialysis Patients 
Dabigatran and rivaroxaban are eliminated through the 
kidneys, hence their use in dialysis patients is discouraged 
because these drugs can accumulate and cause inadvertent 
bleeding. Nevertheless, a steady increase of dabigatran and 
rivaroxaban use has been recorded among 29,977 
hemodialysis patients with atrial fibrillation in the USA, 
where 5.9% of anticoagulated dialysis patients are started 
on these new anticoagulants, with consequent higher risk 
of hospitalization or death from bleeding when compared 
with warfarin (rate ratio 1.48 for dabigatran, P=0.0001) 
and 1.38 for rivaroxaban, P=0.04). The risk of 
hemorrhagic death was even larger with dabigatran (rate 
ratio, 1.78; P=0.006) and rivaroxaban (rate ratio, 1.71; 
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P=0.07) relative to warfarin. Differences in stroke and 
arterial embolism could not be detected in this study as 
there were too few events. The authors concluded that 
more dialysis patients are being started on dabigatran and 
rivaroxaban, even when their use is contraindicated and 
there are no studies to support that the benefits outweigh 
the risks of these drugs in end-stage renal disease (Chan 
KE et al, Circulation 2015; 131: 972-979).  
TRA 2°P - TIMI 50 Trial: Vorapaxar in Patients With 
Diabetes Mellitus and Previous Myocardial Infarction 
Reduces CV Risk but Increases Bleeding 
In patients with diabetes (DM) and prior MI (n=3623), 
barring those with prior TIA or stroke (whereby the drug 
is contraindicated), vorapaxar significantly reduced the 
primary end point (cardiovascular-CV death, MI, or 
stroke) (11.4% vs 14.3%; hazard ratio-HR, 0.73; P=0.002) 
with a number needed to treat to avoid 1 major CV event 
of 29. The incidence of bleeding was increased with 
vorapaxar (4.4% vs 2.6%; HR, 1.60). However, net clinical 
outcome (efficacy and safety) was improved with 
vorapaxar (HR, 0.79). The authors concluded that in 
patients with previous MI and DM, vorapaxar added to 
standard therapy significantly reduced the risk of major 
CV events, albeit at a cost of increased bleeding (Cavender 
MA et al, Circulation 2015; 131: 1047-1053).   
Reduced Cardiovascular and Mortality Risks in 
Elderly Medicare Patients with Atrial Fibrillation (AF) 
Treated With Dabigatran Compared to Warfarin, but 
Increased Major Gastrointestinal Bleeding Risk 
Among 134 414 Medicare patients with 37 587 person-
years of follow-up, the hazard ratios comparing dabigatran 
with warfarin were 0.80 for ischemic stroke; 0.34 for 
intracranial hemorrhage; 1.28 for major gastrointestinal 
(GI) bleeding; 0.92 for acute MI; and 0.86 for death. In the 
subgroup of dabigatran 75 mg bid, there was no difference 
in risk compared with warfarin for any outcome except 
reduced intracranial hemorrhage. The authors concluded 
that dabigatran was associated with reduced risk of 
ischemic stroke, intracranial hemorrhage, and death and 
increased risk of major GI hemorrhage compared with 
warfarin in elderly patients with nonvalvular AF. These 
associations were most pronounced in patients treated with 
dabigatran 150 mg bid, whereas the lower dose of 75 mg 
bid was similar to warfarin except for a lower risk of 
intracranial hemorrhage (Graham DJ et al, Circulation 
2015; 131: 157-164)  
Icatibant, a Selective Bradykinin B2 Receptor 
Antagonist, is Effective in ACE-Inhibitor–Induced 
Angioedema 
All 27 patients with ACE-inhibitor–induced 
angioedema of the upper aerodigestive tract had complete 
resolution of edema with therapy. The median time to 
resolution was 8 hours for those randomly assigned to 30 
mg of subcutaneous icatibant, a selective bradykinin B2 
receptor antagonist, as compared with 27.1 hours in those 
assigned to current off-label standard therapy (IV 500 mg 
prednisolone plus 2 mg clemastine) (P=0.002), with 3 
patients in the standard therapy group requiring rescue 
intervention with icatibant and prednisolone; 1 patient 
required tracheotomy. More patients in the icatibant than 
in the standard-therapy group had complete resolution of 
edema within 4 hours (5 of 13 vs 0 of 14, P=0.02). The 
median time to the onset of symptom relief was shorter 
with icatibant than with standard therapy (2 vs 11.7 hours, 
P=0.03). The authors concluded that among patients with 
ACE-inhibitor–induced angioedema, the time to complete 
resolution of edema was shorter with icatibant than with 
combination therapy with a glucocorticoid and an 
antihistamine (Bas M et al, N Engl J Med 2015; 372:418-
425).  
Good Efficacy of a Device that Narrows the Coronary 
Sinus in Refractory Angina 
A total of 104 patients with refractory (CCS class III or 
IV) angina and myocardial ischemia, who were not 
candidates for revascularization, were randomized to 
implantation of a balloon-expandable, stainless steel, 
hourglass-shaped, coronary-sinus reducing device 
(creating a focal narrowing and increasing pressure in the 
coronary sinus, thus redistributing blood into ischemic 
myocardium) (treatment group, n=52)) or to a sham 
procedure (control group, n=52). More (35% vs 15%) 
patients in the treatment compared to the control group had 
an improvement of at least two CCS angina classes at 6 
months (P=0.02), or improvement of at least one CCS 
angina class (71% vs 42%; P=0.003). Quality of life was 
significantly improved in the treatment vs control group 
(P=0.03), with no significant between-group differences in 
improvement in exercise time or in the mean change in the 
wall-motion index by dobutamine echocardiography. At 6 
months, 1 patient in the treatment group had a myocardial 
infarction (MI); in the control group, 1 patient died and 3 
had an MI. The authors concluded that implantation of the 
coronary-sinus reducing device was associated with 
significant improvement in symptoms and quality of life in 
patients with refractory angina who were not candidates 
for revascularization (Verheye S et al, N Engl J Med 2015; 
372:519-527).   
BEST Trial: Bypass Surgery (CABG) Superior to 
Second Generation (Everolimus-Eluting) Stents in 
Multivessel Coronary Artery Disease (CAD) 
A total of 880 patients with multivessel CAD were 
randomized to PCI with everolimus-eluting stents (n=438) 
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or to CABG (n=442). At 2 years, the primary end point 
(death, MI, or target-vessel revascularization) occurred in 
11% vs 7.9% in the 2 groups, respectively (P=0.32 for 
noninferiority). At longer-term follow-up (median, 4.6 
years), the primary end-point had occurred in 15.3% vs 
10.6% (hazard ratio, 1.47; P=0.04). Rates of any repeat 
revascularization and spontaneous MI were significantly 
higher after PCI than after CABG. The authors concluded 
that among patients with multivessel CAD, the rate of 
major adverse cardiovascular events was higher among 
those who underwent PCI with use of everolimus-eluting 
stents than among those having CABG (Park S-J et al, N 
Engl J Med 2015; 372:1204-1212).   
Clinical-Practice Registry Study Comparing Second 
Generation Stenting with Bypass Surgery: Similar 
Risk of Death but Higher Risk of MI and Repeat 
Procedures and Lower Risk of Stroke with PCI 
At a mean follow-up of 2.9 years of 18,446 patients, 
9223 patients undergoing PCI with everolimus-eluting 
stents and 9223 having CABG, PCI vs CABG had similar 
risk of death (3.1% vs 2.9% per year; hazard ratio-HR, 
1.04; P=0.50), higher risks of MI (1.9% vs 1.1% per year; 
HR, 1.51; P<0.001, only for those with incomplete 
revascularization) and repeat revascularization (7.2% vs 
3.1% per year; HR, 2.35; P<0.001), and a lower risk of 
stroke (0.7% vs 1.0% per year; HR, 0.62; P<0.001). The 
authors concluded that the risk of death with PCI was 
similar to that associated with CABG. PCI was associated 
with a higher risk of MI (among patients with incomplete 
revascularization) and repeat revascularization but a lower 
risk of stroke (Bangalore S et al, N Engl J Med 2015; 
372:1213-1222).   
In-stent Restenosis Detected by Angiographic 
Surveillance in 10 004 patients is Predictive of 4-Year 
Mortality Even in Asymptomatic Patients  
Among 10 004 stented patients undergoing routine 
control angiography after 6-8 months, restenosis was 
detected in 2643 (26.4%) patients. Of 702 deaths occurring 
during follow-up, 218 occurred among patients with 
restenosis and 484 deaths in patients without restenosis 
(hazard ratio- HR: 1.19; P = 0.03). Restenosis was an 
independent predictor of 4-year mortality; HR: 1.23; P = 
0.02). Other independent correlates of 4-year mortality 
were age (for each 10-year increase, HR: 2.34; P < 0.001), 
diabetes mellitus (HR: 1.68; P < 0.001), current smoking 
habit (HR: 1.39; P = 0.01), and left ventricular ejection 
fraction (for each 5% decrease, HR: 1.39; P < 0.001). The 
authors concluded that the presence of restenosis at follow-
up angiography after coronary stenting was predictive of 
4-year mortality, even in patients that were asymptomatic. 
The evidence of restenosis provided prognostic 
information complementary to that provided by other 
clinical characteristics (age, gender, diabetes mellitus, 
smoking, previous by-pass surgery, ejection fraction). 
These findings suggest that newer-generation drug-eluting 
stents may have a meaningful impact on long-term 
mortality through the reduction in restenosis after coronary 
stenting (Cassesse S et al, Eur Heart J 2015; 36: 94-99).   
Network Meta-Analysis: Effectiveness of PFO Closure 
Depends on the Device Used / PFO Closure With 
Ampatzer Occluder Appears Superior to Medical 
Therapy in Preventing Strokes in Patients with 
Cryptogenic Embolism 
A network meta-analysis of 4 randomized trials (2963 
patients with 9309 patient-years) including 3 devices 
(Amplatzer, STARFlex, and HELEX) indicated that 
patients allocated to PFO closure with Amplatzer were less 
likely to experience a stroke than patients allocated to 
medical therapy (rate ratio -RR 0.39), while no significant 
differences were found for the other devices. No 
significant differences were found for transient ischemic 
attack and death. The risk of new-onset atrial fibrillation 
was more pronounced for STARFlex (RR 7.67), than 
Amplatzer (RR 2.14) and HELEX (RR 1.33), when 
compared with medical therapy. The authors concluded 
that network meta-analysis provided evidence in favour of 
percutaneous closure of PFO with one of the examined 
devices (Amplatzer) in patients with a history of 
cryptogenic stroke or embolism and a PFO (Stortecky S et 
al, Eur Heart J 2015; 36: 120-128).   
ANSWER Study: AAI-DDD Changeover Mode to 
Minimize Ventricular Pacing (SafeR) Compared to 
DDD Mode did not Reduce Heart Failure (HF) 
Hospitalization or Atrial Fibrillation (AF) 
A total of 650 patients (52% sinus node disease, 48% 
AV block) were randomized to SafeR (n = 314) or DDD 
(n = 318) mode. The SafeR mode showed a significant 
decrease in ventricular pacing (VP) compared with DDD 
(11.5 vs 93.6%, P < 0.0001 at 3 years). Deaths and syncope 
did not differ in the two groups. No significant difference 
was found in the time to event of the co-primary composite 
of hospitalization for HF, AF, or cardioversion, nor in the 
individual components. However, SafeR showed a 51% 
risk reduction (RR) in experiencing cardiac death or HF 
hospitalization (hazard ratio-HR = 0.49; P = 0.02) and 30% 
RR in experiencing cardiovascular hospitalizations (HR = 
0.70; P = 0.05). The authors concluded that SafeR vs DDD 
safely and significantly reduced VP with no effect on 
hospitalization for HF, AF, or cardioversion, but admitted 
that the favourable effect of SafeR-mediated VP 
prevention on HF outcomes warrants further investigation, 
as the combined clinical secondary outcome of cardiac 
40 
 
death or HF hospitalization differed in favour of the SafeR 
group, with an observed borderline significant reduction in 
cardiovascular hospitalizations and shorter duration of 
hospital stay for these hospitalizations (Stockburger M et 
al, Eur Heart J 2015;36:151-157).   
Ibaraki Study: Presence of Atrial Premature Beats 
(APBs) in 12-Lead ECGs is Associated with Increased 
Risk of Cardiovascular (CV) Death and New-Onset 
Atrial Fibrillation (AF) in the General Population 
Among 63,197 individuals (mean age, 58.8 ± 9.9 years; 
67.6% women) who participated in annual community-
based health checkups, during a 14-year mean follow-up, 
in subjects with APBs, compared with those without 
APBs, the hazard ratio (HRs) of stroke death was 1.24 for 
men and 1.63 for women, of CV death 1.22 for men and 
1.48 for women, and of all-cause death 1.08 for men and 
1.21 for women. The presence of APBs at baseline was 
also a significant predictor of AF onset (HR 4.87 for men 
and 3.87 for women). The authors concluded that the 
presence of APBs in 12-lead ECGs was a strong predictor 
of AF development, and associated with increased risk of 
CV death in the general population (Murakoshi N et al, Eur 
Heart J 2015;36:170-178).  
 
Analysis of 6563 Aspirin-Treated Patients in ACTIVE-
A and AVERROES: Patients with Permanent AF are 
at a Higher Risk of Stroke Compared with Patients 
with Non-Permanent AF / in Deciding whether to Offer 
Anticoagulation to Low-Risk Patients, it May be Useful 
to Consider the Pattern of AF Occurrence 
Among 6563 aspirin-treated patients with AF from the 
ACTIVE-A/AVERROES databases (mean age: 69 ± 9.9 
for paroxysmal, 68.6 ± 10.2 for persistent, and 71.9 ± 9.8 
years for permanent AF (P < 0.001), the CHA2DS2-VASc 
score was similar in patients with paroxysmal and 
persistent AF (3.1 ± 1.4), but higher in permanent AF (3.6 
± 1.5, P < 0.001). Annual stroke rates were 2.1% for 
paroxysmal, 3% for persistent, and 4.2% for permanent 
AF, with hazard ratio of 1.83 (P < 0.001) for permanent vs 
paroxysmal and 1.44 (P = 0.02) for persistent vs 
paroxysmal. Age ≥ 75 years, gender, history of stroke or 
TIA, and AF pattern were independent predictors of stroke, 
with AF pattern being the second strongest predictor after 
prior stroke or TIA. The authors concluded that among 
non-anticoagulated AF patients, pattern of AF was a strong 
independent predictor of stroke risk and may be helpful to 
assess risk/benefit for anticoagulant therapy in lower risk 
patients (Vanassche T et al, Eur Heart J 2015;36:281-288).  
 
ROCKET-AF Trial: Higher Risk of Death and Stroke 
in Persistent vs Paroxysmal Atrial Fibrillation (AF) 
Of 14,062 patients in the ROCKET-AF trial, 11,548 
(82%) had persistent and 2,514 (18%) had paroxysmal AF. 
Patients with persistent AF were marginally older (73 vs 
72, P = 0.03), less likely female (39 vs 45%, P < 0.0001), 
and more likely to have prior use of vitamin K antagonists 
(64 vs 56%, P < 0.0001) compared with patients with 
paroxysmal AF. In patients randomized to warfarin, time 
in therapeutic range was similar (58 vs 57%, P = NS). 
Patients with persistent AF had higher rates of stroke or 
systemic embolism (2.18 vs 1.73 events per 100-patient-
years, P = 0.048) and all-cause mortality (4.78 vs 3.52, P 
= 0.006). Rates of major bleeding were similar (3.55 vs 
3.31, P = NS). Rates of stroke or systemic embolism in 
both types of AF did not differ by treatment assignment 
(rivaroxaban vs warfarin). The authors concluded that 
patients with persistent AF have a higher risk of stroke and 
death compared with paroxysmal AF (Steinberg BA et al, 
Eur Heart J 2015;36:288-296). 
 
The Swedish Atrial Fibrillation (AF) Cohort Study: 
Stroke Benefit from Anticoagulation, but Higher Risk 
of Bleeding in Patients with AF and Renal Failure 
In a retrospective non-randomized study of Swedish 
health registers comprising 307,351 patients with AF, 
ischemic stroke occurred more often among 13,435 with 
prior diagnosis of renal failure (annual rate, 3.9% vs no 
renal failure, 2.9%), but this was related to concomitant 
comorbidities (hazard ratio -HR 1.02). Adding renal 
failure to the established risk stratification (CHADS2 and 
CHA2DS2-VASc) did not improve predictive value. Renal 
failure was an independent risk factor for intracranial 
bleeding (HR: 1.27). Most patients with renal failure 
benefited from warfarin treatment, despite their high 
bleeding risk. The incidence of the combined endpoint 
ischemic or hemorrhagic stroke or death was lower among 
those who used warfarin (HR: 0.76). The authors 
concluded that patients with AF and renal failure will 
probably benefit most from having same treatment as is 
recommended for other patients with AF, by careful 
considerations of net benefit, optimal management of other 
risk factors for stroke and bleeding, and rigorous control of 
INR. Adding additional points for renal failure to the 
CHA2DS2-VASc score did not improve predictive value 
(Friberg L et al, Eur Heart J 2015; 36: 297-306).  
 
Denmark Cohort Study: Thromboembolic Risk 
Beyond 3 Months after Radiofrequency Ablation 
(RFA) of AF is Relatively Low  
During a median follow-up of 3.4 years of 4050 patients 
(median age 59.5, 26.5% females) undergoing first-time 
RFA, 71 (1.8%) thromboembolism cases were identified, 
where incidence rates with and without oral 
anticoagulation (OAC) were 0.56 and 0.64, respectively. 
Discontinuation of OAC remained insignificant (hazard 
ratio-HR 1.42) in multivariable analysis. Beyond 3 months 
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after RFA, 87 (2.1%) serious bleedings occurred 
(incidence rates with and without OAC 0.99 and 0.44, 
respectively). OAC therapy was significantly associated 
with serious bleeding risk (HR 2.05). In an age- and 
gender-matched cohort of 15,848 non-ablated AF patients 
receiving rhythm-control therapy, thromboembolic rates 
with and without OAC were 1.34 and 2.14, respectively. 
The authors concluded that thromboembolic risk beyond 3 
months after RFA was relatively low compared with a 
matched non-ablated AF cohort. With cautious 
interpretation due to low number of events, serious 
bleeding risk associated with OAC seems to outweigh the 
benefits of thromboembolic risk reduction. The CHA2DS2-
VASc score may not be an appropriate tool for 
thromboembolic risk stratification in this population 
(Karasoy D et al, Eur Heart J 2015;36: 307-315).  
 
MADIT-CRT Trial: in Patients with LBBB, 
Biventricular (BIV) Pacing >90% Confers Benefit of 
Cardiac Resynchronization Therapy-Defibrillator 
(CRT-D) in Heart Failure (HF)/Death when Compared 
with Implantable Cardioverter Defibrillator (ICD)  
The threshold of BIV pacing percentage needed for 
CRT-D to be superior to ICD on the end-point of heart 
failure (HF) or death was estimated in 1219 left bundle 
branch block (LBBB) patients in the MADIT-CRT trial 
(NYHA class I /II HF patients in sinus rhythm). In multi-
variable analyses, no difference was seen in the risk of HF/ 
death between ICD and CRT-D patients with BIV pacing 
≤90% (HR = 0.78, P=NS), and with increasing BIV pacing 
the risk of HF/death was decreased (CRT-D BIV 91–96% 
vs ICD: HR = 0.63, P = 0.024; and CRT-D BIV ≥97% vs 
ICD: HR = 0.32, P < 0.001). The risk of death alone was 
reduced by 52% in CRT-D patients with BIV ≥97% (HR = 
0.48, P<0.016), when compared with ICD patients. Within 
the CRT-D group, for every 1% increase in BIV pacing, 
the risk of HF/death and death alone significantly decrea-
sed by 6 and 10%, respectively. The authors concluded that 
in patients with LBBB, BIV pacing >90% was associated 
with a benefit of CRT-D in HF/death when compared with 
ICD patients. Also, BIV pacing ≥97% was associated with 
an even further reduction in HF/death, a significant 52% 
reduction in death alone, and increased reverse remodel-
ling. Physicians should be aware of patients with subopti-
mal BIV pacing to implement preventive and optimizing 
measures to improve outcome and prognosis in these 
patients (Ruwald A et al, Eur Heart J 2015;36: 440-448).  
 
CONFIRM-HF: Beneficial Effects of Long-term 
Intravenous (IV) Iron Therapy in Patients with 
Symptomatic Heart Failure and Iron Deficiency 
A total of 304 heart failure (HF) patients with left 
ventricular ejection fraction ≤45%, elevated natriuretic 
peptides, and iron deficiency (ferritin <100 ng/mL or 100–
300 ng/mL if transferrin saturation <20%), were 
randomized 1:1 to IV iron, as ferric carboxymaltose (FCM, 
n = 152) or placebo (saline, n = 152) for 52 weeks. 
Treatment with FCM significantly prolonged 6-min-walk-
test (6MWT) distance at Week 24 (difference FCM vs 
placebo: 33 ± 11 m, P = 0.002). The treatment effect of 
FCM was consistent in all subgroups and was sustained to 
Week 52 (difference FCM vs placebo: 36 ± 11 m, P < 
0.001). Throughout the study, an improvement in NYHA 
class, patient global assessment, quality of life (QoL), and 
fatigue score in patients treated with FCM was detected 
with statistical significance observed from Week 24 
onwards. Treatment with FCM was associated with a 
significant reduction in the risk of hospitalizations for 
worsening HF (hazard ratio: 0.39, P = 0.009). The number 
of deaths (FCM: 12, placebo: 14 deaths) and the incidence 
of adverse events were comparable between groups. The 
authors concluded that treatment of symptomatic, iron-
deficient HF patients with FCM over a 1-year period 
resulted in sustainable improvement in functional capacity, 
symptoms, and QoL and may be associated with risk 
reduction of hospitalization for worsening HF 
(Ponikowski P et al, Eur Heart J 2015; 36 : 657-668).  
 
Systemic Review & Meta-analysis: Thrombolysis is 
Associated with a Significant Reduction of Mortality in 
Patients with Pulmonary Embolism (PE), but this 
Reduction is not Statistically Significant after 
Exclusion of Studies with High-Risk PE, While it is 
Associated with an Increase in Fatal, Intracranial, or 
Major Hemorrhage 
According to meta-analysis of 15 randomized trials 
comparing thrombolytic therapy plus anticoagulation with 
anticoagulation alone in 2057 patients with acute 
pulmonary embolism (PE), thrombolytic therapy was 
associated with a significant reduction of overall mortality 
(OR; 0.59). This reduction was not statistically significant 
after exclusion of studies including high-risk PE (OR; 
0.64). Thrombolytic therapy was associated with a 
significant reduction in the combined endpoint of death or 
treatment escalation (OR: 0.34), PE-related mortality (OR: 
0.29) and PE recurrence (OR: 0.50). Major hemorrhage 
(OR; 2.91) and fatal or intracranial bleeding (OR: 3.18) 
were significantly more frequent among patients receiving 
thrombolysis. The authors concluded that thrombolytic 
therapy reduces total mortality, PE recurrence, and PE-
related mortality in patients with acute PE, albeit at 
increased risk of major and fatal or intracranial 
hemorrhage. The decrease in overall mortality is, however, 
not significant in hemodynamically stable patients with 
acute PE (Marti C et al, Eur Heart J 2015;36: 605-614).  
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ABSORB II Trial: Stents with Bioresorbable Scaffold 
Had 1-year Clinical Outcome Similar to Metallic Stents 
A total of 501 patients undergoing percutaneous 
coronary intervention were randomly assigned (2:1 ratio) 
to the bioresorbable scaffold stent group (everolimus-
eluting bioresorbable scaffold) (335 patients, 364 lesions) 
or the metallic stent group (everolimus-eluting metallic 
stent) (166 patients, 182 lesions). Acute lumen gain was 
lower for the bioresorbable scaffold. At 1 year, cumulative 
rates of first new or worsening angina were lower (22%) 
in the bioresorbable scaffold group (vs 30% in the metallic 
stent group; p=0·04), whereas performance during 
maximum exercise and angina status were similar. Three 
patients in the bioresorbable scaffold group had stent 
thromboses, compared with no patients in the metallic 
stent group. There were 5% major cardiac adverse events 
in the bioresorbable scaffold group compared with 3% 
events in the metallic stent group, with the most common 
events being myocardial infarction and need for target-
lesion revascularisation. The authors concluded that 
everolimus-eluting bioresorbable scaffold showed similar 
1-year clinical outcomes to the everolimus-eluting metallic 
stent (Serruys PW et al, Lancet 2015;385:43-54). 
 
RUTHERFORD-2: In Patients with Heterozygous 
Familial Hypercholesterolemia, PCSK9 Inhibition 
With Evolocumab was Well Tolerated and Yielded 
Rapid 60% Reductions in LDL Cholesterol Compared 
with Placebo 
A total of 331 patients with heterozygous familial 
hypercholesterolemia were randomly assigned to 4 
treatment groups: evolocumab 140 mg every 2 weeks 
(n=111), evolocumab 420 mg monthly (n=110), placebo 
every 2 weeks (n=55), or placebo monthly (n=55). 
Compared with placebo, evolocumab at both dosing 
schedules led to a significant reduction in mean LDL 
cholesterol at week 12 (every-2-weeks dose: 59.2% 
reduction, monthly dose: 61.3% reduction; both p<0.0001) 
and at the mean of weeks 10 and 12 (60.2% reduction and 
65.6% reduction; both p<0.0001). Evolocumab was well 
tolerated, with rates of adverse events similar to placebo. 
The most common adverse events occurring more 
frequently in the evolocumab-treated patients were 
nasopharyngitis (9% vs 5%) and muscle-related adverse 
events (5% vs 1%). The authors concluded that in patients 
with heterozygous familial hypercholesterolemia, 
evolocumab administered either 140 mg every 2 weeks or 
420 mg monthly was well tolerated and yielded rapid 60% 
reductions in LDL cholesterol compared with placebo 
(Raal FJ et al, Lancet 2015;385:331-340).  
 
TESLA Part B Trial: Inhibition of PCSK9 with 
Evolocumab in Patients with Homozygous Familial 
Hypercholesterolemia on Lipid-Lowering Therapy and 
not on Apheresis, Significantly Reduced LDL 
Cholesterol Compared with Placebo 
Patients (N=49), aged ≥12 years, with homozygous 
familial hypercholesterolemia, on stable lipid-regulating 
therapy for at least 4 weeks, and not receiving lipoprotein 
apheresis, were randomly assigned (2:1 ratio) to receive 
subcutaneous evolocumab 420 mg (n=33) or placebo 
(n=16) every 4 weeks for 12 weeks. Compared with 
placebo, evolocumab significantly reduced LDL 
cholesterol at 12 weeks by 30.9% (p<0.0001). Adverse 
events occurred in 10 (63%) of 16 patients in the placebo 
group and 12 (36%) of 33 in the evolocumab group. No 
serious clinical or laboratory adverse events occurred, and 
no anti-evolocumab antibody development was detected 
during the study. The authors concluded that in patients 
with homozygous familial hypercholesterolemia, 
evolocumab was well tolerated and significantly reduced 
LDL cholesterol compared with placebo (Raal FJ et al, 
Lancet 2015;385:341-350).  
 
International Carotid Stenting Study (ICSS) Trial: 
Long-term Outcomes Similar After Stenting or 
Endarterectomy for Treatment of Symptomatic 
Carotid Stenosis  
A total of 1710 patients with symptomatic carotid 
stenosis were randomly assigned to open treatment with 
stenting (n=855) or endarterectomy (n=858) and followed 
up for a median of 4.2 years. The number of fatal or 
disabling strokes (52 vs 49) and cumulative 5-year risk did 
not differ between the stenting and endarterectomy groups 
(6.4% vs 6·5%; hazard ratio -HR 1.06, p=NS). Any stroke 
was more frequent in the stenting group than in the 
endarterectomy group (119 vs 72 events (p=0.04), but were 
mainly non-disabling strokes. The authors concluded that 
long-term functional outcome and risk of fatal or disabling 
stroke are similar for stenting and endarterectomy for 
symptomatic carotid stenosis (Bonati LH et al, Lancet 
2015;385:529-538).  
 
SIMPLE Study: Routine Defibrillation Testing (DFT) 
at the Time of ICD Implantation is Well Tolerated, but 
does not Improve Shock Efficacy or Reduce 
Arrhythmic Death  
A total of 1253 patients having an implantable 
cardioverter defibrillator (ICD) implantation were 
randomly assigned to defibrillation testing (DFT) and 1247 
to no-testing, and followed up for a mean of 3.1 years. The 
primary outcome of arrhythmic death or failed appropriate 
shock occurred in fewer patients (7% per year) in the no-
testing group than patients who did receive it (8% per year; 
HR 0.86). The first safety composite outcome occurred in 
5.6% of patients with no-testing and in 6.5% of patients 
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with DFT (p=NS). The second, pre-specified safety 
composite outcome, which included only events most 
likely to be directly caused by testing, occurred in 3.2% of 
patients with no-testing and in 4.5% with DFT, p=0.08. 
Heart failure needing intravenous treatment with inotropes 
or diuretics was the most common adverse event (2% in 
both groups). The authors concluded that routine DFT at 
the time of ICD implantation is generally well tolerated, 
but does not improve shock efficacy or reduce arrhythmic 
death (Healey J et al, Lancet 2015;385:785-791) 
 
Systematic Review and Meta-analysis: Extended 
Duration Dual Antiplatelet Therapy is not Associated 
with a Difference in Risk of Total, Cardiovascular 
(CV), or non-CV Mortality 
 
Including the Dual Antiplatelet Therapy (DAPT) 
Study, which showed that continuation of dual antiplatelet 
therapy beyond 12 months after coronary stenting was 
associated with an unexpected increase in non-CV death, 
14 trials were identified that randomly assigned 69,644 
participants to different durations of dual antiplatelet 
therapy. Compared with aspirin alone or short duration 
dual antiplatelet therapy (≤6 months), continued treatment 
was not associated with a difference in all-cause mortality 
(hazard ratio -HR 1.04; p=NS). Similarly, CV (HR 1.01) 
and non-CV mortality (HR 1.04; p=NS) were no different 
with extended duration versus short duration dual 
antiplatelet therapy or aspirin alone. The authors 
concluded that extended duration dual antiplatelet therapy 
was not associated with a difference in the risk of all-cause, 
CV, or non-CV death compared with aspirin alone or short 
duration dual antiplatelet therapy (Elmariah S et al, Lancet 
2015;385:792-798).  
 
Cardiac Screening of Low-Risk Adults with Functional 
Stress Testing: No Evidence that it Improves Patient 
Outcomes, while it Confers Increased Costs and 
Potential Harms 
 
Literature review indicates that cardiac screening in 
adults with resting or stress electrocardiography, stress 
echocardiography, or myocardial perfusion imaging has 
not been shown to improve patient outcomes. 
Contrariwise, it may be associated with potential harms 
due to false-positive results as it can lead to subsequent, 
potentially unnecessary tests and procedures. It is 
particularly inefficient in adults at low risk for coronary 
artery disease due to low prevalence and predictive values 
of testing in this population and low likelihood that 
positive findings will affect treatment decisions. It is 
preferable that clinicians focus on strategies that reduce 
cardiovascular risk by modifying and managing risk 
factors, such as smoking, diabetes, hypertension, 
hyperlipidemia, and obesity, while encouraging exercise 
and healthy diet. The authors conclude that clinicians 
should not screen for cardiac disease in asymptomatic, 
low-risk adults with resting or stress electrocardiography, 
stress echocardiography, or stress myocardial perfusion 
imaging (Chou R et al, Ann Intern Med 2015;162:438-
447).  
 
Population-Based Case-Control Study: Association of 
Amiodarone Use and Risk of Acute Pancreatitis 
 
According to a Taiwanese case-control study involving 
4986 subjects (aged 20–84) with a first episode of acute 
pancreatitis and 19,944 matched subjects without acute 
pancreatitis, current use of amiodarone was positively 
associated with acute pancreatitis (odds ratio 5.21). There 
was no significant association between recent or past 
amiodarone use and acute pancreatitis. The authors 
concluded that patients with current use of amiodarone are 
at an increased risk of acute pancreatitis (Lai S et al, Heart 
Rhythm 2015;12:163-166).  
 
Permanent His-Bundle Pacing is Feasible in Routine 
Clinical Practice 
 
With use of the Select Secure (model 3830) pacing lead 
via a guiding catheter, His bundle pacing (HBP) was 
attempted in 94 consecutive patients, while 98 patients 
underwent right ventricular pacing (RVP). HBP was 
successful in 75 patients (80%) with similar fluoroscopy 
time, albeit higher pacing threshold compared with the 
RVP group (1.35±0.9 V vs 0.6±0.5 V at 0.5 ms; P < 0.001) 
that remained stable over a 2-year follow-up period. In 
patients with >40% ventricular pacing (>60% of patients), 
heart failure hospitalization was significantly reduced in 
the HBP group (2% vs 15%; P = 0.02), with no difference 
in mortality (13% vs 18%; P = NS). The authors concluded 
that permanent HBP without a mapping catheter was 
successfully achieved in 80% of patients, displaying higher 
pacing threshold, but achieving better clinical outcomes 
(Sharma PS et al, Heart Rhythm 2015; 12:305-312).  
 
Implantable Devices (Defibrillators-ICDs/Pacemakers-
PPMs) Exacerbate Tricuspid Regurgitation (TR) 
which Confers Higher Mortality Risk 
 
Among 1,596 patients (aged 60 ± 10 years, 61% men) 
who had cardiac devices implanted (62% ICDs or CRT-D; 
38% PPMs), the prevalence of grade 3 or 4+ TR increased 
from 27% to 31% by 1 month and to 35% at 4 years. 
Device type (ICD vs PPM) and the number of leads placed 
did not have an effect on post-procedural TR. Right 
ventricular systolic pressure did not change over time. 
One-year and 5-year survival was 93% and 73%, 
respectively. Post-procedural TR was an independent risk 
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factor for late death (P < 0.05). The authors concluded that 
cardiac device implantation was associated with a small 
but significant increase in the prevalence of moderate and 
severe TR, both acutely and chronically after implantation, 
similar for both ICD and PPM placement, not related to the 
number of leads implanted. Postimplantation TR was 
associated with a higher risk of mortality (Al-Bawardy R 
et al, Pacing Clin Electrophysiol 2015;38:259-266).  
 
Systematic Review and Meta-Analysis: Blood Pressure 
Lowering Improves Survival in Type 2 Diabetes 
 
Analysis of 40 randomized controlled trials (100,354 
participants) of blood pressure (BP) lowering in diabetics 
indicated that each 10-mm Hg lower systolic BP was 
associated with a significantly lower risk of mortality 
(relative risk -RR, 0.87); absolute risk reduction (ARR) in 
events per 1000 patient-years (3.16), cardiovascular events 
(RR, 0.89; ARR, 3.90), coronary artery disease (RR, 0.88; 
ARR, 1.81), stroke (RR, 0.73; ARR, 4.06), albuminuria 
(RR, 0.83; ARR, 9.33), and retinopathy (RR, 0.87; ARR, 
2.23). The associations between BP-lowering treatments 
and outcomes were not significantly different, irrespective 
of drug class, except for stroke and heart failure. The 
authors concluded that among patients with type 2 
diabetes, BP lowering was associated with improved 
clinical outcomes with lower RRs observed among those 
with baseline BP of >140 mm Hg (Emdin CA et al, JAMA 
2015;313:603-615).  
 
Reperfusion Success is Influenced by Thrombus 
Burden, which May be Improved by Mesh-Covered 
Stents in Acute Myocardial Infarction  
 
Among 433 patients with ST elevation myocardial 
infarction (STEMI) randomized to the mesh-covered 
MGuard stent vs a control bare-metal or drug-eluting stent, 
angiographically visible thrombus was identified in 383 
patients (88.5%). Lesions with large thrombus were treated 
more frequently with manual aspiration (80.8% vs 65.8%, 
p= 0.0009) and longer and larger stents. Percutaneous 
coronary intervention (PCI) of lesions with large thrombus 
burden had more thrombotic complications (30.6% vs 
15.9%, p= 0.0007) and reduced angiographic success 
(80.3% vs 91.1%, p= 0.003). In lesions with large 
thrombus, the MGuard stent was more effective than 
control stents in achieving TIMI-3 flow (87.9% vs 74.5%, 
p= 0.02) and tended to result in less slow flow or no reflow 
(8.8% vs 17.6%, p= 0.07). The authors concluded that 
reperfusion success is reduced after primary PCI in lesions 
with large thrombus burden, an outcome that may be 
improved by the MGuard stent (Costa RA et al, Am J 
Cardiol 2015;115;161-166).  
 
 
Obstructive Sleep Apnea (OSA) is a Predictor of Stroke 
in Patients With Atrial Fibrillation (AF) 
Of 5,138 patients screened for obstructive sleep apnea 
(OSA), 402 (7.7%) had AF and 332 (6.4%) constituted the 
study population, whereby the occurrence of first-time 
stroke was 22.9%. Ischemic stroke was more common in 
patients with OSA (25.4% vs 8.2%, p= 0.006; odds ratio 
3.65). Subgroup analysis showed significantly higher rates 
of stroke in patients with CHADS2 scores of 0 and 
CHA2DS2-VASc scores of 0 and 1 and co-morbid OSA. 
The authors concluded that OSA in patients with AF is an 
independent predictor of stroke (Yaranov DM et al, Am J 
Cardiol 2015; 115:461-465).  
 
Important Review and Other Articles  
Central sleep apnea in heart failure (Costanzo MR et al, 
J Am Coll Cardiol 2015;65:72-84), Remote ischemic 
preconditioning (Heusch G et al, J Am Coll Cardiol 2015; 
65:177-195), Substrate modification for AF ablation 
(Kottkamp H et al, J Am Coll Cardiol 2015;65:196-206), 
Device-detected AF (Chen-Scarabelli C et al, J Am Coll 
Cardiol 2015;65:281-294), Hyponatremia in acute heart 
failure (Verbrugge FH et al, J Am Coll Cardiol 2015;65: 
480-492), Sudden death in the older athlete (Chugh SS & 
Weiss JB, J Am Coll Cardiol 2015;65:493-502), 
Revascularization in severe LV dysfunction (Velazquez EJ 
& Bonow RO, J Am Coll Cardiol 2015;65:281-294), The 
myth of the “vulnerable plaque” (Arbab-Zadeh A & Fuster 
V, J Am Coll Cardiol 2015;65:846-855), Peripheral artery 
disease (Patel MR et al, J Am Coll Cardiol 2015;65:931-
941), Angiotensin receptor antagonism-neprilysin 
inhibitor therapy in heart failure (Braunwald E, J Am Coll 
Cardiol 2015;65:1029-1041), Dietary sodium (Farquhar 
WB et al, J Am Coll Cardiol 2015;65:1042-1050), 
Secondary (functional) mitral regurgitation (Asgar AW et 
al, J Am Coll Cardiol 2015;65:1231-1248), Porcelain aorta 
(Abramowitz Y et al, Circulation 2015;131:827-836), 
AHA statement on secondary prevention after coronary 
bypass (Kulik A et al, Circulation 2015;131:927-964), 
Left atrial appendage occlusion (Whitlock RP et al, 
Circulation 2015;131:756-761), Disorders of plasma 
sodium (Sterns RH, N Eng J Med 2015; 372:55-65), 
Carotid artery stenting (Cremonesi A et al, Eur Heart J 
2015;36:13-21), Air pollution and cardiovascular disease 
(Newby DE et al, Eur Heart J 2015;36:83-93), Myocardial 
infarction with no obstructive coronary atherosclerosis 
(Niccoli G et al, Eur Heart J 2015; 36;475-481), Ularitide 
for treatment of acute heart failure (Anker SD et al, Eur 
Heart J 2015;36:715-723), Cryptogenic stroke and silent 
atrial fibrillation (Glotzer TV & Ziegler PD, Heart Rhythm 
2015;12:234–241), Early repolarization syndrome 
(Mahida S et al, Heart Rhythm 2015;12:242-249),  
